Why did LNAI stock skyrocket over 130% pre-market today?

Lunai Bioworks, Inc. (LNAI) surged over 130% pre-market after announcing a $20 million acquisition of Alzheimer's assets and blood-brain barrier delivery tech from the Clemann Group. This deal, structured as Series B Convertible Preferred shares, aims to significantly advance the company's capabilities in central nervous system drug development.